Skip to main content
. 2019 Jun 26;38(15):e95874. doi: 10.15252/embj.201695874

Figure 5. Clinical relevance of PTRF and IGFBP7 and drug activity.

Figure 5

  • A–D
    (A–C) Immunohistochemical staining for PTRF and (D) statistical analysis by one‐way ANOVA based on PFS. *P‐value < 0.05; **< 0.01, ***< 0.001.
  • E
    Kaplan–Meier curves with hazard ratio correlating PFS and TTD (time to death) with PTRF expression.
  • F
    IGFBP7 analysis by one‐way ANOVA in the serum samples of patients with MAPKi therapy by ELISA. *P‐value < 0.05.